Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 663–664 | Cite as

ASO Author Reflections: Is Intensifying Loco-Regional Treatment in the Early Course of De Novo Stage IV Breast Cancer Reasonable?

  • Atilla SoranEmail author
ASO Author Reflections



The author has no conflicts of interest to disclose.


  1. 1.
    Soran A, Ozbas S. Surgery for the primary tumor in patients with de novo stage IV breast cancer. In: Aydiner A, İğci A, Soran A, eds. Breast disease, management, and therapies, Volume 2. Springer, Switzerland; 2016:455–64.Google Scholar
  2. 2.
    Bishop AJ, Ensor J, Moulder SL, et al. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015;121(24):4324–32. Epub 2015 Sep 8.CrossRefGoogle Scholar
  3. 3.
    Wong Y, Raghavendra AS, Hatzis C, et al. Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2)-positive breast cancers treated with HER2-targeted therapy. Oncologist. 2018. pii: theoncologist.2018-0213. [Epub ahead of print].
  4. 4.
    Soran A, Ozmen V, Ozbas S. randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–9. Epub 2018 May 17. PMID:29777404.CrossRefGoogle Scholar
  5. 5.
    Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer (SUBMIT)
  6. 6.
    Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer (POSYTIVE)
  7. 7.
    Standard of care therapy with or without stereotactic radiosurgery and/or surgery in treating patients with limited metastatic breast cancer.
  8. 8.
    Early surgery or standard palliative therapy in treating patients with stage IV breast cancer.
  9. 9.
    A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Pittsburgh Medical Center, Magee-Womens HospitalPittsburghUSA

Personalised recommendations